TARGETING HEMOSTASIS DYSFUNCTION AND INFLAMMATION IN COVID-19 PATIENTS: POTENTIAL THERAPEUTICS AVENUES THROUGH VIRAL AND HOST MOLECULES

The COVID-19 pandemic has presented magnitude of challenges for global health authorities and researchers alike. The World Health Organization (WHO) is overseeing innumerable clinical studies aimed at determining the potency of existing drug against the virus. Concurrently, scientists worldwide are analysing into the cellular and molecular mechanisms underlying SARS-CoV-2 infection. Studies indicate that assorted factors such as blood haemostasis dysfunction, hypoxia, venous thrombotic and inflammation events play crucial roles in the evolution of COVID-19, from its early stage to several expressions. Understanding how the virus instigates these detrimental cellular and biochemical processes is predominant. This mini review explores budding trends in the pathophysiology of COVID-19 and discusses therapeutic perspectives. Researchers are striving to untwist how SARS-CoV-2 triggers adverse cellular and biochemical reactions in infected individuals, offering hope for the progression of effective treatments.

Key-Words: Hemostasis, COVID-19, SARS-CoV-1, Inflammation, Host Cells, Cytokines